<?xml version="1.0" encoding="UTF-8"?>
<p>Accordingly, there are reasons for optimism in TB vaccine development. New strategic directions include diversifying the pipeline to explore candidates that generate immunity beyond CD4+ Th1 T-cells, including non-conventional, cellular immunity and trained innate immunity 
 <sup>
  <xref rid="ref-19" ref-type="bibr">19</xref>
 </sup>; assessing new routes of vaccine administration, including aerosol and, possibly, intravenous approaches; investigating the extent to which antibody generating vaccines may contribute to protection afforded by the current, cell-mediated immune generating candidates; and utilizing new tools for vaccine candidate R&amp;D, including positron emission tomography-computerized tomography (PET-CT) scans 
 <sup>
  <xref rid="ref-20" ref-type="bibr">20</xref>
 </sup> and bar-coded 
 <italic>Mtb</italic> strains 
 <sup>
  <xref rid="ref-21" ref-type="bibr">21</xref>
 </sup> permitting ultrasensitive assessments of animal challenge models, and a potential controlled human infection model (CHIM) for 
 <italic>Mtb</italic>
 <sup>
  <xref rid="ref-22" ref-type="bibr">22</xref>, 
  <xref rid="ref-23" ref-type="bibr">23</xref>
 </sup>. These new strategic directions in TB vaccine development add to the sense of optimism and excitement in the field.
</p>
